An increase in neuronal activity triggers the transcription of immediate early genes, including the proto-oncogene c-fos, which, in turn, stimulates the transcription of AP-1-promotorcontaining late response genes that are responsible for adaptive changes in mature neurons (1, 2). It is well established that the concentration of second messengers and differences in the activation threshold for calcium-dependent signaling are important factors controlling cellular responses to stimulatory signals, including the transcriptional activation of Fos genes (3, 4). Two key regulators of c-fos transcription are the phosphorylated forms of mitogen-activated protein kinase (MAPK) 1 and CREB (4). CREB is a Ca 2ϩ /cAMP-responsive transcription factor that in its phosphorylated form (pCREB; phosphorylated at Ser 133 ) stimulates transcription of the c-fos gene by interacting with the CRE transcriptional regulatory element (for review see Ref.
1
and CREB (4) . CREB is a Ca 2ϩ /cAMP-responsive transcription factor that in its phosphorylated form (pCREB; phosphorylated at Ser 133 ) stimulates transcription of the c-fos gene by interacting with the CRE transcriptional regulatory element (for review see Ref. 2) . The MAPK cascade is thought to participate in the activation of c-fos transcription either by phosphorylating CREB at Ser 133 or by phosphorylating ternary complex factors that, together with serum response factor, bind to the SRE element of the c-fos promotor (2) . Activation of the MAPK cascade occurs in response to serum or growth factor stimulation (5) as well as in response to increased calcium levels via a Ras-dependent pathway (6) .
Induction of c-fos expression is an important mechanism in the control of neurotransmitter-regulated gene expression. One extensively studied example is the dopamine-regulated expression of Fos (7) . In the striatum, for example, induction of c-fos expression has been shown to occur in response to the acute administration of cocaine and amphetamine (8 -13) . These drugs indirectly activate dopamine receptors, and the Fos responses elicited by them have been linked to the activation of dopamine D 1 -like receptors, which couple to stimulatory subsets of heterotrimeric proteins to stimulate cytosolic second messengers (14) . Moreover, blockade of dopamine D 2 -like receptors (which couple to inhibitory G proteins) by neuroleptic drugs results in increased c-fos expression levels. Anatomically, a close topographic relationship exists between c-fos effects and the expression of receptors upon which various typical and atypical neuroleptics act (15) (16) (17) (18) . Furthermore, if mesotelencephalic dopaminergic neurons are destroyed by 6-hydroxydopamine, neuroleptic drugs no longer increase c-fos expression levels, indicating that dopamine exerts a tonic inhibitory effect on basal c-fos levels via its action on D 2 -like receptors (15) .
Pharmacological studies further revealed synergistic c-fos responses to combined D 1 -and D 2 -like receptor stimulation in the striatum of normal and dopamine-depleted rats (19 -21) . Whereas the topographic overlap between increase in c-fos expression and expression of receptors blocked by various neuroleptic drugs suggest a cellular mechanism that regulates basal c-fos-expression levels, synergistic c-fos responses to combined D 1 -and D 2 -like receptor stimulation are more likely to be regulated at the level of neuronal circuitry.
The studies that found synergistic effects of D 1 -and D 2 -like receptor activation on c-fos responses (20, 21) used D 2 -like agonists that do not discriminate between the D 2 and D 3 receptor subtypes (for review see Ref. 22) . Thus, it remains unresolved whether D 2 and D 3 receptors contribute similarly or differently to the modulation of c-fos responses. However, the current lack of antagonists specific for each member of the D 2 class of dopamine receptors complicates attempts to elucidate the role of both receptor subtypes in the modulation of c-fos expression levels. Therefore, the present study used mutant mice generated by gene targeting via homologous recombination that lack D 2 Male animals at postnatal ages P15, P30, P60, and P70 were used in this study. Their genotypes were verified by Southern blotting as described in Jung et al. (23) . Animals were housed in a 12-h light/dark cycle colony room at 22°C with free access to food and water. The following drugs were administered: 1 mg/kg SKF82958, 1 mg/kg SCH23390, and 0.5 mg/kg eticlopride. All drugs were purchased from Research Biochemicals, Inc. (Natick, MA). Drugs were dissolved in saline and administered intraperitoneally between 2 and 5 p.m. Animals were killed at defined time points after systemic drug administration, and their brains were quickly removed. The dorsal striatum (caudoputamen) was immediately dissected from all brains. This dissection did not include the ventral part of the striatum containing the nucleus accumbens. The dorsal striatal tissue and the remaining brain tissue were collected in separate tubes and stored at Ϫ80°C until use. All animal procedures were approved by the Institutional Animal Care and Use Committee.
Expression of c-fos, pMAPK, and pCREB Immunoreactivities-For immunoblot analyses (c-fos, pMAPK, and pCREB), proteins were extracted in a buffer containing 1ϫ phosphate-buffered saline, 1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% SDS (RIPA buffer) supplemented with 2 mM Na 3 VO 4 , 20 mM NaF, 1 mM EGTA, 1 mM dithiothreitol, 1 M microcystin, and protease inhibitors. The protein concentration in each lysate was determined using the BCA protein assay kit (Pierce).
c-fos immunoreactivity was detected with two different rabbit polyclonal anti-c-fos antibodies. One antibody was purchased from Santa Cruz (Santa Cruz, CA; lot number H067) and used at a dilution of 1:1000. The other antibody (dilution, 1:2,500 to 1:5000) was obtained from Oncogene Research (San Diego, CA; lot number D08330). A sheep polyclonal anti-phospho MAPK antibody (Upstate Biotechnology, Inc., Lake Placid, NY) was used at a dilution of 1:1000, and a rabbit polyclonal anti-pCREB antibody (Upstate Biotechnology) was used at a dilution of 1:2,500. A mouse monoclonal anti-TH antibody (Incstar, Stillwater, MN; dilution, 1:10,000) was used to reprobe all immunoblots. Bound antigen was visualized using the appropriate peroxidaseconjugated secondary antibodies (Kirkegaard & Perry Laboratories, Gaithersburg, MD) in conjunction with ECL (Pierce). The ECL signals on autoradiograms were assessed densitometrically using the National Institutes of Health Image Analysis Software. Optical density measurements of standards on the film were made to construct a standard correlation curve. Relative optical densities were determined for optical densities of signals located in equal size sample areas. (21, 24) . A first series of experiments performed on wild type animals determined the time course of c-fos induction and tested whether D 1 -and D 2 -like receptor antagonists block or reduce this induction.
RESULTS

The
As shown in Fig. 1A , the earliest time point at which a robust induction of expression of c-fos can be detected on Western blots is 60 min after the systemic application of the drug. In general, however, the onset of detectable c-fos expression varies between 60 and 90 min, a variability that is most likely accounted for by the route of drug administration (i.e. intraperitoneal). c-fos immunoreactivity remains detectable up to 120 min after drug administration and then returns to base-line levels (not shown). In addition to the induction of c-fos expression, SKF82958 administration also leads to phosphorylation of the MAPK. The kinetics of MAPK phosphorylation is more rapid and increased levels of pMAPK immunoreactivity are detected 20 min after drug administration (Fig. 1A) . The expression levels of pMAPK return to base line 30 -45 min after drug administration (not shown). Interestingly, although the anti-pMAPK antibody recognizes the phosphorylated pMAPK When SKF82958 was administered to mice at P15, only a marginal (and barely detectable) c-fos response was detected in all animals, regardless of their genotype. A representative example of c-fos responses in the striatum of these mice is shown in Fig. 2C . Thus, a robust c-fos expression in response to D 1 agonist stimulation occurs only at most advanced postnatal ages. In fact, the differences in c-fos responses of P30 and P60 mice suggest that the maturity of c-fos responses correlates with the maturity of the animal.
Despite of the differences in c-fos responses seen in D 2 and D 2 /D 3 mutants at P30 and P60, c-fos levels of D 3 single mutants are consistently lower at both postnatal ages. To test whether possible differences in the genetic background could have accounted for the lower c-fos responses to SKF82958 in brains of D 3 single mutants, additional experiments were performed with congenic (C57Bl/6) D 3 mutants and their wild type littermates. As shown in Fig. 3 , also congenic D 3 mutants showed a substantial reduction in the levels of c-fos expressed following SKF treatment. Fig. 3A shows a representative example of a Western blot of proteins extracted from brain (without striatum) tissue that was probed with the same antibody used to probe the blots shown in Fig. 2 (a rabbit polyclonal anti-c-fos antibody; Santa Cruz). Identical results were obtained when the blot was probed with another polyclonal anti-c-fos antibody (Oncogene Research) (Fig. 3B ). This antibody, like the first antibody, recognizes an epitope located within peptide sequences that constitute the amino terminus of the c-fos protein.
Unlike the first antibody, however, the second antibody does not recognize other nonspecific protein bands (like the one migrating above the c-fos band in Fig. 2 ). In fact, it recognizes exclusively one major c-fos protein of 55 kDa and a second protein of 57 kDa that is known to result from posttranslational modifications of the 55-kDa c-fos protein (25) . A densitometric analysis of signals shown in Fig. 3B revealed an optical density of 2.95 for the entire field containing c-fos signals of wild type animals 45, 60, 90, and 120 min after SKF treatment. The optical density for an equal size field containing corresponding signals of D 3 mutants is only 1.68, indicating a 57% reduction in c-fos expression levels. Thus, the results obtained with congenic D 3 mutants are very similar to the results obtained with hybrid (129Sv ϫ C57Bl/6) D 3 mutant mice (Fig. 2B) . Moreover, Fig. 3C illustrates that, similar to the results shown in Fig. 2A , congenic D 3 mutants also express lower levels of dorsal striatal c-fos immunoreactivity in response to D 1 agonist stimulation. Optical density measurements of these signals (wild type, 4.84; D 3 mutants, 1.42) revealed a 70% reduction of c-fos levels in D 3 mutants.
The next experiments tested whether the D 2 -like antagonist eticlopride would further affect the D 1 agonist-stimulated c-fos response of D 3 mutants. The results are summarized in Fig. 4 . As expected, in both extrastriatal and striatal tissue, administration of eticlopride (0.5 mg/kg) alone does not lead to detectable c-fos expression levels. It should be noted that in the experiment shown in Fig. 4 , the c-fos responses of mice treated with SKF alone are low at 60 min and robust at 90 min after drug administration, whereas c-fos responses of mice treated with eticlopride and SKF are clearly detectable at both time points. As outlined above, the onset of detectable c-fos expression following the systemic administration of SKF varies between 60 and 90 min. This variability in the kinetics of c-fos induction necessitates that c-fos levels are measured at 60 and 90 min after drug administration so that the sums of optical densities of both time points can be compared. In Fig. 4A , results of duplicate experiments on extrastriatal tissues of mice treated with SKF and eticlopride and mice treated with SKF alone are compared. The optical density of the 60-and 90-min signals obtained from SKF-treated animals is 7.74. By comparison, the mean optical density of the 60-and 90-min c-fos signals of animals treated with SKF and eticlopride is 4.43. Thus, a 43% reduction of c-fos expression levels is found in mice pretreated with eticlopride. Similar results are obtained for the dorsal striatum (Fig. 4B) Immunoblotting experiments were performed with pCREBand pMAPK-specific antibodies to test whether the levels of pCREB and pMAPK differ between wild type and the various mutants that received SKF82958 treatment (1 mg/kg). These experiments were done with C57Bl/6 ϫ 129Sv hybrid mice. As shown in Fig. 6 , SKF administration led to the expression of similar levels of pCREB and pMAPK in wild type, D 2 and D 3 single mutants, and D 2 /D 3 double mutants. The slightly lower level of pCREB immunoreactivity shown in Fig. 6 for D 3 mutants could not be verified with additional pCREB immunoprecipitation experiments (not shown). Thus, the results indicate that differences in the expression levels of pCREB and pMAPK do not account for the differences seen in the c-fos responses described above. Differences in c-fos responses between wild type and D 3 mutants were found in mice with a hybrid C57Bl/6 ϫ 129Sv genetic background as well as in congenic C57Bl/6 mice. Thus, it is unlikely that differences in the genetic background contributed to the reduced c-fos expression found in SKF-treated D 3 mutants. Furthermore, the observed differences in c-fos responses to D 1 agonist stimulation cannot be explained by differences in D 1 receptor expression levels in D 3 mutants. Previous studies (27, 28) , as well as our own unpublished results, have shown that the expression of D 1 receptor ligandbinding sites is unaltered in these mutants.
It is also unlikely that the D 1 -selective agonist used in the present study exerts its effects on c-fos induction not only via D 1 but also via D 2 receptors. SKF82958 has recently been reported to act as a D 2 -like autoreceptor agonist to inhibit the basal firing rate of midbrain dopaminergic units (29) . However, as shown in the present study, c-fos responses elicited by (36) . Furthermore, in contrast to previous reports (37, 38) , results of our studies on the expression of D 3 receptor protein (detected with D 3 -specific monoclonal antibodies) and D 3 -encoded mRNA revealed a significant amount of D 3 receptor expression in the dorsal striatum (23, 39) . In addition, imunocytochemical studies on rodent brain tissues identified a high number of D 3 -immunoreactive neurons that possibly represent medium spiny cells and many (but not all) large interneurons. 2 Results of single-cell polymerase chain reaction studies further revealed that ϳ50% of the substance P/D 1 receptor-expressing neurons also expressed D 3 and D 4 receptor mRNA, and results of electrophysiological studies suggest that ϳ50% of all mediumspiny projection neurons co-express functional D 1 -and D 2 -like receptors (36) . These findings give weight to the possibility that a cellular mechanism underlies the modulatory effects of D 2 and D 3 receptors. However, it should be noted that the effects of D 2 and D 3 receptor expression on c-fos responses to D 1 agonist stimulation are not restricted to the dorsal striatum as previously suggested (20) . We found that it also operates in extrastriatal brain regions. Because the extrastriatal tissues that we analyzed comprised the entire brain (without dorsal striatum), we can only suggest that the c-fos immunoreactivity detected therein is derived mainly from anatomic regions representing the mesolimbic/mesocortical dopaminergic projection areas that express D 1 , D 2 , and D 3 receptors. For these anatomic structures, however, evidence for co-localization of all three receptors is still lacking.
Despite the present uncertainty regarding the contribution of cellular or intercellular mechanisms, determining the point at which D 1 , D 2 , and D 3 receptor-mediated signals converge to regulate the transcriptional activity of the c-fos gene will be an important next step toward understanding the mechanism of dopaminergic regulation of c-fos expression. Our finding that the expression of two key regulators of c-fos transcription, pCREB and pMAPK, is not significantly altered in D 1 agonisttreated mice that lack either D 2 or D 3 receptors suggests that the activity of other components of the signaling/transcriptional activator cascade is modulated by D 2 and D 3 receptors and that these components are most likely operating downstream of CREB and MAPK activation.
Implications of the Findings-Although D 3 receptors were identified by molecular cloning almost a decade ago, it has proven difficult to elucidate the function of these receptors with conventional pharmacological studies (22) . Recently, however, a behavioral study on D 3 mutant mice showed that one role of D 3 receptors is to diminish the normal cooperative effects of D 1 and D 2 receptor stimulation in the regulation of motor activity and responses to the rewarding properties of psychostimulants (28) . The present study identified another role, namely a cooperative participation of D 3 receptors in the regulation of c-fos responses to D 1 agonist stimulation. The finding that D 3 receptors play a role in dopamine-regulated gene expression adds an important new aspect to our understanding of D 3 receptor expression and function.
